FY2022 EPS Estimates for Celldex Therapeutics, Inc. (NASDAQ:CLDX) Increased by Analyst

Celldex Therapeutics, Inc. (NASDAQ:CLDX – Get Rating) – Investment analysts at Jefferies Financial Group raised their FY2022 earnings estimates for Celldex Therapeutics in a note issued to investors on Tuesday, June 21st. Jefferies Financial Group analyst C. Howerton now forecasts that the biopharmaceutical company will post earnings of ($1.85) per share for the year, up from their prior forecast of ($1.87). The consensus estimate for Celldex Therapeutics’ current full-year earnings is ($2.01) per share. Jefferies Financial Group also issued estimates for Celldex Therapeutics’ FY2023 earnings at ($2.33) EPS and FY2024 earnings at ($2.75) EPS.

Celldex Therapeutics (NASDAQ:CLDX – Get Rating) last released its quarterly earnings results on Thursday, May 5th. The biopharmaceutical company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.03). Celldex Therapeutics had a negative net margin of 1,860.46% and a negative return on equity of 20.68%. The firm had revenue of $0.17 million during the quarter, compared to analyst estimates of $0.75 million.

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Celldex Therapeutics in a research note on Tuesday, March 1st. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $65.00.

Shares of NASDAQ CLDX opened at $26.14 on Thursday. Celldex Therapeutics has a 1-year low of $19.85 and a 1-year high of $57.20. The company has a market cap of $1.22 billion, a PE ratio of -15.29 and a beta of 2.72. The company has a 50-day moving average of $27.79 and a two-hundred day moving average of $31.72.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Denali Advisors LLC bought a new stake in shares of Celldex Therapeutics during the fourth quarter worth approximately $43,000. Point72 Hong Kong Ltd raised its stake in shares of Celldex Therapeutics by 57.9% during the first quarter. Point72 Hong Kong Ltd now owns 1,394 shares of the biopharmaceutical company’s stock worth $47,000 after buying an additional 511 shares during the last quarter. Captrust Financial Advisors bought a new stake in shares of Celldex Therapeutics during the third quarter worth approximately $88,000. Prospera Financial Services Inc bought a new stake in shares of Celldex Therapeutics during the first quarter worth approximately $89,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Celldex Therapeutics by 35.1% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,610 shares of the biopharmaceutical company’s stock worth $191,000 after buying an additional 1,459 shares during the last quarter. 98.61% of the stock is owned by institutional investors and hedge funds.

Celldex Therapeutics Company Profile (Get Rating)

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation.

Featured Stories